In 2009, two pharmaceutical giants recognized an urgent need in global health: the HIV epidemic required focused, dedicated attention that broader healthcare companies couldn't fully provide. ViiV Healthcare was established through a pioneering partnership between GlaxoSmithKline and Pfizer, with Shionogi joining in 2012, to become the world's only company 100% dedicated to HIV research, treatment, and care. This bold venture was created to take a fresh, innovative approach to the challenge of HIV - and to do things differently.
Today, ViiV Healthcare stands as a global specialist HIV company, driven by a singular mission: to leave no person living with HIV behind. Our team of more than 1,300 scientists, innovators, and believers works tirelessly to push the boundaries of what's possible in HIV treatment and prevention. We've delivered breakthrough medicines that transformed HIV from a fatal condition into a manageable chronic disease, and we're investing in research toward a cure. But we know medicines alone aren't enough. We work in partnership with communities affected by HIV, supporting initiatives that combat stigma and improve access to care. From our innovative portfolio of antiretroviral treatments to our commitment to implementation science that bridges research and real-world practice, we're here until HIV isn't.